PLX

PROTALIX BIOTHER
AMEX

Real-time Quotes | Nasdaq Last Sale

2.220
+0.030
+1.37%
After Hours: 2.250 +0.03 +1.35% 17:55 04/03 EDT
OPEN
2.190
PREV CLOSE
2.190
HIGH
2.290
LOW
2.169
VOLUME
75.14K
TURNOVER
--
52 WEEK HIGH
5.19
52 WEEK LOW
1.700
MARKET CAP
32.94M
P/E (TTM)
-1.8024
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PLX stock price target is 154.25 with a high estimate of 300.00 and a low estimate of 8.50.

EPS

PLX News

More
  • Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement
  • PR Newswire · 03/18 17:12
  • Edited Transcript of PLX earnings conference call or presentation 12-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 03/16 12:27
  • Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein
  • PR Newswire · 03/16 11:50
  • Protalix BioTherapeutics' (PLX) CEO Dror Bashan on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/12 15:49

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.
More

Webull offers kinds of Protalix Biotherapeutics Inc stock information, including AMEX:PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions.